Diligence memo · auto-generated · as of July 2, 2026

Torax Medical Inc

Torax Medical Inc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Torax Medical Inc operates in Biotechnology, based in SHOREVIEW.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Torax Medical Inc has raised $77M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $25M on 2016-07-15.

Most recent recorded round closed around 2016-07-15.

Valuation (modeled)modeled

Provath models Torax Medical Inc at approximately $992M (range $50M–$3.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.25× the median modeled value of Series B Biotechnology companies in 2016–2018 (101 peers) — value vs value, same stage and era. Within the normal band (125% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 17 months.

Last raise 10.0 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.8× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 87% of Biotechnology peers (4293 compared).

Modeled value ranks above 89% of those peers.

Closest niche peers: Liquid BioScience, Inc., Amphivena Therapeutics, Inc., Tracon Pharmaceuticals, Inc., Tetra Discovery Partners, Inc., ECM Therapeutics, Inc..

Peoplefiled

17 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.